ERBB2 and breast cancer: The difference is that paclitaxel- and anthracycline-based regimens for chemotherapy are preferred for the HR-negative subgroup (TNBC) in HER2-negative BC, regardless of early and late stages, whereas endocrine therapy is generally preferred in the HR-positive subgroup (luminal A/luminal B).